Filgrastim Recruiting Phase 2 Trials for Myelodysplastic Syndromes / Acute Lymphoblastic Leukaemias (ALL) / Myeloproliferative Disorders / Lymphoma, Hodgkins / Leukemias / Non Hodgkin Lymphoma (NHL) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Acute / Myelodysplastic-Myeloproliferative Diseases Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03434730Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
NCT03164057A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT03860844Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT02782546Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
NCT03045627Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients
NCT02275663Azacytidine Plus FLAG for Relapsed or Refractory AML
NCT03318419Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
NCT03646123Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
NCT03755804Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17